跳至主要内容
临床试验/EUCTR2014-001193-34-ES
EUCTR2014-001193-34-ES进行中(未招募)1 期

COMPARISON OF TWO ANTIRETROVIRAL ALTERNATIVE COMBINATIONS IN HIV-1 POST-EXPOSURE PROPHYLAXIS: TENOFOVIR+EMTRICITABINE (TRUVADA®) + LOPINAVIR/RITONAVIR (KALETRA®) VS TENOFOVIR+EMTRICITABINA+ COBICISTAT + ELVITEGRAVIR (STRIBILD®). A PROSPECTIVE RANDOMIZED OPEN-LABEL STUDY. - STRIB-PEP

Fundació Clínic per a la recerca biomèdica0 个研究点开始时间: 2014年7月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. equal to or more than 18 years old.
  • 2 have suffered exposure to HIV, not occupational , and which meets the requirements of the current recommendations to initiate PEP with three antiretroviral drugs.
  • 3 that, properly informed, you grant your consent in writing to participate in the study and submit to the tests and scans that entails.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 180
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1 pregnant women, nursing mothers, or those who intend to become pregnant during the study period.
  • 2. subjects that is known or suspected that the source case presented resistance to any of the guidelines of the study drugs.
  • 3. treatment with drugs that are contraindicated with the study, or products under investigation.

研究者

发起方
Fundació Clínic per a la recerca biomèdica

相似试验